Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Free Report) has been given an average recommendation of “Hold” by the five analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.75.
A number of analysts have recently weighed in on the stock. StoneX downgraded shares of Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a report on Wednesday, November 11th. Benchmark lifted their price objective on shares of Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research note on Wednesday, August 12th. Stonex Financial cut shares of Harvard Bioscience from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Weiss Ratings upgraded shares of Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. Finally, Zacks Research assumed coverage on shares of Harvard Bioscience in a research report on Tuesday, November 3rd. They set a “hold” rating for the company.
View Our Latest Analysis on HBIO
Hedge Funds Weigh In On Harvard Bioscience
Harvard Bioscience Trading Up 1.9%
HBIO stock opened at $9.08 on Friday. The business has a 50-day simple moving average of $8.38 and a 200 day simple moving average of $6.62. Harvard Bioscience has a 52 week low of $4.00 and a 52 week high of $10.20. The company has a quick ratio of 0.86, a current ratio of 1.76 and a debt-to-equity ratio of 7.28.
Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. The business had revenue of $22.20 million during the quarter, compared to analysts’ expectations of $21.80 million. Equities research analysts predict that Harvard Bioscience will post -2.44 EPS for the current fiscal year.
About Harvard Bioscience
Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.
See Also
- Five stocks we like better than Harvard Bioscience
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
